886 Shares in United Therapeutics Corporation $UTHR Acquired by BAM Wealth Management LLC

BAM Wealth Management LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 886 shares of the biotechnology company’s stock, valued at approximately $432,000.

Other hedge funds have also recently added to or reduced their stakes in the company. AE Wealth Management LLC grew its position in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc acquired a new position in United Therapeutics during the third quarter worth $444,000. Simplify Asset Management Inc. bought a new position in shares of United Therapeutics in the third quarter valued at $8,351,000. Finally, Osaic Holdings Inc. lifted its stake in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company boosted their price objective on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $586.00.

United Therapeutics Price Performance

NASDAQ UTHR opened at $564.81 on Monday. The company has a fifty day moving average price of $506.70 and a 200-day moving average price of $479.77. The firm has a market cap of $24.76 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the firm earned $6.19 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
• Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $581.63, for a total transaction of $5,525,485.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,563,576.19. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $25,561,479.64. The trade was a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 339,270 shares of company stock worth $171,740,110. Insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.